Skip to main content

View full-text article in PMC

. 2019 Dec 10;12:577. doi: 10.1186/s13071-019-3836-6

Table 2.

Distribution of ERR and CR among the study population and by infection intensity

	Egg reduction rate (ERR)							Cure rate (CR)
	Post dose 1			Post-dose 3			P-value^c	Post-dose 1			Post-dose 3			P-value^c
	e/E^a	%	P-value	e/E^a	%	P-value		n/N^b	%	P-value	n/N^b	%	P-value
Study population	309/4369	92.9		408/7953	94.9	–	0.003	52/67	77.6		72/82	87.8	–	0.15
Age			< 0.0001			< 0.0001	< 0.0001			0.95^d			0.91	0.78
6–8	5/313	98.4		7/2017	99.7			10/12	83.3		13/15	86.7
9–11	69/1727	96.0		70/2739	97.4			19/25	76.0		24/27	92.0
12–14	223/1420	84.3		99/1514	93.5			16/21	76.2		21/25	88.9
15–23	12/909	98.7		232/1683	86.2			7/9	77.8		14/15	93.3
Gender			< 0.0001			< 0.0001	< 0.0001			0.058			0.09	0.007
Female	7/1914	99.6		41/4602	99.1			27/30	90.0		39/41	95.1
Male	302/2455	87.7		367/3351	89.0			25/37	67.6		33/41	80.5
Location						0.020
Bindo	0/1	100		38/512	92.6			1/1	100		3/4	75.0
Zilé-PK	309/4368	92.9		370/7441	95.0		0.0001	51/66	77.3		69/78	88.5		0.12
Infection intensity			< 0.0001			< 0.0001	< 0.0001			0.01^d			0.004^d	< 0.0001
Light	57/519	89.0		2/566	99.6			40/46	87.0		45/46	97.8
Heavy	252/3850	93.5		406/7387	94.5			12/21	57.1		27/36	75.0

^aE is the total Schistosoma egg counts at baseline and e is the total Schistosoma egg counts at control

^bN is the number of participants treated at baseline and n is the number of participants found negative at control

^cP-value to assess the significant difference observed between post-dose 1 and post-dose 3 results

^dFisher’s exact test applied

Note: The ERR and CR was assessed at PZQ post-dose1 (n = 67) and post-dose 3 (n = 82)